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Abstract Theiler’s murine encephalomyelitis virus (TMEV)
infection of a susceptible strain of mice results in virus
persistence in the brain and chronic primary immune-mediated
demyelination, which resembles multiple sclerosis. Recent atten-
tion has focused on the anti-inflammatory and immunosuppres-
sive properties of interleukin-6, a pleiotropic cytokine involved in
the regulation of immunological responses, acute phase protein
production and hematopoiesis. Anandamide (arachidonoyl etha-
nolamine) is a natural brain constituent that binds a specific
brain cannabinoid receptor. In this study we investigated whether
anandamide can modify interleukin-6 production by primary
cultures of murine brain cortical astrocytes infected with TMEV.
Astrocytes from susceptible (SJL/J) and resistant (BALB/c)
strains of mice infected with TMEV (105 PFU/well) increased
IL-6 release over a period of 24 h. Anandamide caused an
enhancement of the release of IL-6 by TMEV-infected astrocytes
in a concentration-dependent manner (1^25 WM). Treatment of
TMEV-infected astrocytes with 10 WM arachidonyl trifluoro-
methyl ketone, a potent inhibitor of the amidase that degrades
anandamide, was found to potentiate the effects of anandamide
on IL-6 release. A novel and selective cannabinoid receptor
antagonist, SR 141617A, blocked the enhancing effects of
anandamide on IL-6 release by TMEV-infected astrocytes,
suggesting a cannabinoid receptor-mediated pathway. The
physiological implications of these results are unknown, but
may be related to the hypothesis of the protective effects of
cannabinoids on neurological disorders like multiple sclerosis.
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1. Introduction
Susceptible mouse strains infected with Theiler’s murine
encephalomyelitis virus (TMEV), a picornavirus which has
the mouse as its natural host, present lesions closely resem-
bling those of multiple sclerosis (MS). The pathogenesis of
demyelination in TMEV infection is considered to be depend-
ent on the host immune response against the virus [1,2]. As-
trocytes respond promptly to CNS injury and infection and
are e⁄ciently infected by TMEV [3,4]. Under such circum-
stances, astrocytes produce in£ammatory mediators and sev-
eral cytokines, including interleukin-6 [5]. Interleukin-6 (IL-6)
is a pleiotropic cytokine involved in the regulation of in£am-
matory and immunological responses, acute phase protein
production, and hematopoiesis. Increased IL-6 mRNA ex-
pression in blood and cerebrospinal £uid monocellular cells
has been described in patients with MS [6]. Although initially
considered to be a pro-in£ammatory cytokine, recent ¢ndings
suggest that IL-6 has many anti-in£ammatory and immuno-
suppressive e¡ects [7]. Within the CNS, IL-6 inhibits IFNQ/IL-
1L- and IFNQ/LPS-induced synthesis of TNF-K in glial cells
[8], and suppresses demyelination in a viral (TMEV) model of
MS [9].
Cannabinoids, a class of biologically active compounds, are
best known for their ability to alter CNS function and to
produce immunosuppression. It is now recognized that can-
nabinoids exert their e¡ects by both receptor- and non-recep-
tor-mediated mechanisms. Two cannabinoid receptor sub-
types have been identi¢ed. The ¢rst of these, designated
CB1, is limited to neural tissue, including astrocytes [10],
while the second, designated CB2, is found primarily within
immune cells at peripheral sites [11]. Anandamide (arachidon-
yl ethanolamide) is a naturally occurring brain constituent
that binds to CB1 receptors and is released after neuronal
depolarization [12]. Anandamide biosynthesis is believed to
be mediated by anandamide synthase by using arachidonic
and ethanolamine as substrates in the brain [13] or phospho-
diesterase-mediated cleavage of a novel phospholipid precur-
sor, N-arachidonyl-phosphatidylethanolamine [14]. Anand-
amide behaves as a cannabimimetic compound and in vitro
it stimulates receptor-mediated signal transduction that leads
to the inhibition of forskolin-stimulated adenylate cyclase
[15,16]. It is therefore likely that anandamide may act as an
important regulatory molecule. However, the physiological
role of anandamide has not yet been established.
We have previously reported that anandamide inhibits ni-
tric oxide and TNF-K production by astrocytes stimulated
with LPS or infected with TMEV [17]. These results suggest
that astrocytes are possible target cells for immunomodula-
tory activities of anandamide. In the present study we at-
tempted to investigate the e¡ects of anandamide on IL-6 pro-
duction by TMEV-infected astrocytes and whether
anandamide acts by a cannabinoid receptor pathway.
2. Materials and methods
2.1. Mice
One day postnatal SJL/J (Jackson Laboratories) and BALB/c mice
pathogen free were obtained from the Central Animal Laboratory of
the Cajal Institute (CSIC, Madrid, Spain). Animal care procedures
were accordance with the guidelines set by the European Community
Council Directives (86/609/EEC).
2.2. Virus
TMEV strain Daniel (DA) generously gifted by Dr. Raymon P.
Roos (Department of Neurology, University of Chicago, IL) was
used. The DA strain of TMEV was plaque puri¢ed and passaged
four times in baby hamster kidney cells (BHK-21). Virus was titrated
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and stored in aliquots at 370‡. Virus was used at 1U105 plaque-
forming units (PFU)/ml.
2.3. Astrocyte cultures
Primary astrocyte cultures were prepared from the cerebral cortex
from 1-day-old postnatal SJL/J or BALB/c mice, as previously de-
scribed in detail [18], and grown in T150 £asks for at least 14 days
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) plus 10% heat-in-
activated fetal calf serum (Whittaker, France), 20 mM glutamine
(ICN Biomedicals, California) and gentamicin with the medium being
changed twice weekly. On reaching con£uence (2 weeks) the cells were
shaken at 240 rpm overnight at 37‡C to dislodge cells adhering to the
astrocyte layer (primarily oligodendrocytes and microglia). The media
were replaced and the cells were allowed to recover for 2^3 days
before experiments. To visualize glial ¢brillary acidic protein
(GFAP), cells were ¢xed with 4% paraformaldehyde in PBS for 20
min at room temperature. Afterwards, the cells were washed three
times with PBS and blocked for 15 min in PBS containing 0.2%
BSA, 5% goat serum and 0,2% Triton X-100. Monoclonal anti-
GFAP (1:500; Sigma) was diluted in the same solution and was
applied for 45 min. The second antibody Texas red donkey anti-
mouse (Jackson Immunochemicals) was diluted (1:100) and applied
under the same conditions. The resulting cultures consisted of s 95%
astrocytes as determined by GFAP staining and 6 3% of cells were
positive for the microglia marker Mac-1 (Fig. 1). For stimulation,
astrocyte monolayers were incubated with the virus for 1 h at 37‡C
in serum-free DMEM plus 0.1% BSA. Following incubation the cells
were washed and placed in new medium. On the basis of previous
studies, we selected a dose of 105 PFU/ml. The variations in IL-6
release over a period of 24 h after TMEV infection led us to choose
a post-infection period of 24 h for the experiments with anandamide.
Anandamide (RBI, Natick, MA) at doses of 1, 10 and 25 WM, was
added prior to the TMEV infection and then maintained throughout
the post-infection period. The e¡ect of an inhibitor of anandamide
degradation [19], arachidonyl tri£uoromethyl ketone (Sigma Chemi-
cal, St. Louis, MO), was studied by adding it, together with ananda-
mide. The possible mediation of cannabinoid receptors was studied by
using the selective CRB1 antagonist, SR 141716A (N-(piperidin-1-yl)-
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) 4-methyl-1H-pyrazole-3-
carboxamide hydrochloride), a generous gift of Sano¢ Research [20].
2.4. IL-6 assay
The presence of IL-6 in the harvested supernatants from astrocyte
cultures was investigated using enzyme-linked immunoadsorbent as-
say (Intertest-6X mouse ELISA kit, Genzyme, Cambridge, MA). The
detection limit was 8.8 pg/ml. Coe⁄cients of intra- and inter-assay
variation were 3.1 and 8.7% respectively. There was no detectable
crossreactivity with other cytokines.
2.5. Statistics
The data are presented as mean þ S.E.M. of 3^4 independent deter-
minations and each experiment was carried out in triplicate. Compar-
isons were analyzed using one-way analysis of variance (ANOVA)
followed by the posteriori Student-Newman-Keuls t-test. Statistical
signi¢cance was established at P6 0.05.
3. Results
We initially examined the e¡ect of TMEV infection on IL-6
generation by astrocytes from both susceptible (SJL/J) and
resistant (BALB/c) strains of mice over a period of 24 h. By
phase contrast microscopy, cultures of infected astrocytes
maintained the same cell density and appearance as non-in-
fected cultures, showing no cytopathic e¡ect (not shown). As
illustrated in Fig. 2, cultured astrocytes derived from both
strains of mice were able to produce IL-6 following TMEV
infection. The pattern of IL-6 production was identical in the
two strains of mice, showing the higher levels at 24 h post-
infection. Therefore, in the following experiments with anand-
amide we only used TMEV-infected astrocytes from SJL/J
mice and an interval of post-infection time of 24 h.
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Fig. 1. Immuno£uorescence staining of astrocyte cells in culture with anti-GFAP, using confocal microscopy (Leica 500M).
Fig. 2. Time course of IL-6 release by murine TMEV-infected astro-
cytes (105 PFU/well), derived from susceptible (SJL/J) and resistant
(BALB/c) mouse strains. Results represent the mean þ S.E.M. of a
representative experiment done in triplicate.
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Treatment with anandamide caused a concentration-de-
pendent increase in the release of IL-6 by TMEV-infected
astrocytes (Fig. 3). ANOVA of the results revealed a signi¢-
cant e¡ect of the treatment (F4;30=745.277; P6 0.0000), and a
posteriori test indicated a signi¢cant e¡ect among the three
doses of anandamide employed (P6 0.01 and P6 0.05, re-
spectively). At the highest concentration of anandamide
tested, IL-6 release was increased by 38.52% over IL-6 pro-
duction by TMEV-infected astrocytes. The stimulation of IL-
6 release by anandamide was con¢rmed using an inhibitor of
anandamide degradation. Anandamide is rapidly metabolized
by amidases to arachidonic acid and ethanol amine [18].
Treatment of TMEV-infected astrocytes with 10 WM arachi-
donyl tri£uoromethyl ketone, an inhibitor of amidases, was
found to potentiate signi¢cantly the release of IL-6 by anand-
amide 1 WM (P6 0.01) and 10 WM (P6 0.01) (Fig. 4). This
observation supports a direct signalling role of anandamide.
The actions of cannabinoids are thought to be mediated, in
part, by speci¢c receptors that are expressed on the surface of
responsive cells. A signi¢cant question is therefore whether
anandamide exerts its e¡ects on IL-6 production by binding
to speci¢c receptors in astrocytes. To examine this question
we used a selective antagonist of brain CBR1 receptors,
SR141617A. Under these conditions, the presence of 1 WM
SR141617A blocked the potentiating e¡ect of 10 WM ananda-
mide on IL-6 release by TMEV-infected astrocytes (Table 1),
suggesting a receptor-mediated action of anandamide.
4. Discussion
In the present study we show that anandamide exhibits
immunomodulatory activity in astrocytes as demonstrated
by the enhancement of IL-6 production in response to
TMEV infection. Numerous studies suggest that the host im-
mune response plays a primary role in the initiation of events
leading to myelin destruction in the TMEV model of MS [2,3].
In this model, the main reservoir of virus in the CNS is in-
fected macrophages, but also astrocytes contain viral antigen
[3]. The presence of both IL-6 and IL-6 mRNA in the CNS of
intracranially TMEV-infected mice has been described in pre-
vious studies [5,21]. Elevated levels of IL-6 in the CNS of
EAE diseased animals but not in their spleens are suggestive
of a local production of IL-6 within the brain [22]. Here, we
show that murine astrocytes from both susceptible and resist-
ant strains of mice are able to synthesize IL-6, indicating, in
agreement with other studies [3], that IL-6 seems not to be
involved in determining susceptibility/resistance to the devel-
opment of demyelinating disease.
Exogenous cannabinoids are now known to exert immuno-
modulatory activity. In our study, the endogenous cannabi-
noid anandamide was found to potentiate IL-6 production by
TMEV-infected astrocytes in a dose-dependent manner. This
e¡ect can be attributed to anandamide per se, because experi-
ments performed in the presence of an inhibitor of ananda-
mide degradation showed a potentiation of the e¡ects of
anandamide on IL-6 production. The fact that SR141717A,
a potent and selective antagonist of the brain cannabinoid
receptor, blocked the enhancing e¡ects of anandamide on
IL-6 release suggests the possibility of a cannabinoid recep-
tor-mediated pathway. The lack of activity of anandamide on
spleen cells [23] and the fact that anandamide has only been
identi¢ed in neuronal tissue preparations may be indicative
that anandamide is a neural-speci¢c cannabinoid agonist.
However, there are studies showing that anandamide is able
to inhibit cytokine release, including IL-6, by human mono-
nuclear cells [24]. Furthermore, a second endogenous canna-
binoid ligand, 2-arachidonyl glycerol, isolated from the intes-
tinal tract was shown to inhibit long-term potentiation [25]. It
seems, therefore, that endogenous cannabinoids are able to
FEBS 20613 14-8-98
Fig. 4. E¡ect of the presence of the inhibitor of amidase, arachidon-
yl tri£uoromethyl ketone (ARAK), at a dose of 10 WM on IL-6 re-
lease by TMEV-infected astrocytes treated with 1 and 10 WM
anandamide. Results are the means þ S.E.M. of six experiments.
Statistical di¡erences: *P6 0.001 vs. anandamide 1 WM or 10 WM;
P6 0.001 vs. TMEV.
Table 1
Blockade by SR141617A, a selective antagonist of brain cannabi-
noid receptors, of the e¡ects of anandamide (ANA) on IL-6 release
by TMEV-infected astrocyte
IL-6 (pg/ml)
Control 25.86 þ 1.104
TMEV (105 PFU/ml) 1041.83 þ 13.09***
ANA (10 WM)+TMEV 1499 þ 8.521**
SR141617A (1 WM)+ANA (10 WM)+TMEV 903.33 þ 50.841
SR141617A (1 WM) 48.33 þ 19.30
Results are the mean þ S.E.M. of four experiments. ***P6 0.0001 vs.
control; **P6 0.01 vs. TMEV; P6 0.01 vs. ANA+TMEV.
Fig. 3. E¡ect of di¡erent doses of anandamide on IL-6 release by
TMEV-infected astrocytes. Murine astrocytes from a susceptible
strain of mice (SJL/J) were infected with 105 PFU/well and the
supernatants for IL-6 assay were collected 24 h post-infection. Re-
sults are the mean þ S.E.M. of six experiments. Statistical di¡eren-
ces: *P6 0.001 vs. TMEV; P6 0.01 vs. anandamide 1 WM;
P6 0.05 vs. anandamide 10 WM.
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interact with cannabinoid receptors at both the peripheral and
the central level.
The ¢nding that anandamide activates the release of IL-6
by TMEV-infected astrocytes is consistent with the hypothesis
that anandamide may be a physiologically signi¢cant immu-
noregulatory molecule. This is in line with our previous results
in which anandamide suppressed TNF-K and nitric oxide re-
sponses by stimulated astrocytes [16]. An action of cannabi-
noids in astroglial cells is supported by the presence of the
CB1 receptor in astrocytes and astrocytoma cells [26]. IL-6 is
a multifunctional cytokine that is produced in a variety of
in£ammatory conditions in vivo. In the CNS, IL-6 has multi-
ple e¡ects on neural cells, and may function in an autocrine
manner as glioblastoma, astrocytoma cell lines and primary
astrocyte cultures express speci¢c high a⁄nity receptors for
IL-6 [27]. Although overproduction of IL-6 in brain of trans-
genic mice resulted in important de¢cits, tremors and astro-
gliosis [28], astrocytes secrete nerve growth factor in response
to IL-6 [29]. Increasing evidence pointed to the neuroprotec-
tive role of IL-6 [7]. Although the full range of the anti-in-
£ammatory e¡ects mediated by IL-6 has not been explored in
the brain, IL-6 inhibits IFNQ/IL-1L-induced synthesis of TNF-
K in glial cells at either the post-transcriptional and/or the
post-translational level. The role of IL-6 in MS is unclear.
The intrathecal production of IL-6 in acute meningo-encepha-
litis has been suggested to have desirable e¡ects such as en-
hancement of antiviral antibodies and to promote neural re-
pair [29]. Interestingly, in the MS model induced by TMEV,
administration of human recombinant IL-6 reduced demyeli-
nation and in£ammation in the spinal cord [9]. IL-6 synthesis
activation may therefore represent an important response of
viral-infected astrocytes to anandamide. There are earlier
studies showing bene¢cial e¡ects of the administration of
exogenous cannabinoids such as v9-tetrahydrocannabinol on
demyelination in several experimental models of MS [30]. A
possible protective role of anandamide in MS disease needs to
be clari¢ed in further studies.
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